Alimetry
Non-invasive gastric mapping device for diagnosing gastrointestinal conditions — the first clinically validated diagnostic of its kind. FDA-cleared and NICE-approved, transforming how gastroenterologists diagnose and manage millions of patients who previously had no objective test available to them.
Alimetry develops a non-invasive gastric mapping platform that analyses stomach electrical activity using AI to provide diagnostic insights and personalised treatment options for functional gastrointestinal disorders. The platform replaces invasive procedures with a wearable device and clinician-facing software.
Why we invested
1 in 5 people live with chronic gut disorders, yet diagnosis has barely changed in decades: invasive, slow, and often inconclusive. Alimetry has built the world's first non-invasive gastric mapping device, backed by 10+ years of University of Auckland research, three FDA approvals, and a reimbursement pathway already in motion. Greg and Armen combine world-class science with genuine commercial urgency — the kind of founders who win over the FDA and Stanford's GI motility centre in the same breath. This is a $6B+ global market, and Alimetry is building the new standard of care.
- Headquarters
- Auckland, New Zealand
- GD1 invested
- 2021
- GD1 lead
- Vignesh Kumar
- Founders
- Greg O'Grady, Peng Du, Recep Avci
